Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury

American Journal of Physiology - Renal Physiology

Volumn 311, Issue 2, 2016, Pages F268-F277

  Skrypnyk, Nataliya I ^a   Voziyan, Paul ^a   Yang, Haichun ^a   de Caestecker, Christian R ^a   Theberge, Marie Claude ^c   Drouin, Mathieu ^c   Hudson, Billy ^a,b   Harris, Raymond C ^a   de Caestecker, Mark P ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SYNEOS HEALTH   (United States)

Author keywords

Oxidative stress; Renal fibrosis; Renal function

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; COLLAGEN TYPE 1 ALPHA1; COLLAGEN TYPE 3 ALPHA1; ICOSANOID; ISOFURAN; ISOPROSTANE DERIVATIVE; PYRIDOXAMINE; UNCLASSIFIED DRUG; VITAMIN B COMPLEX;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; HISTOPATHOLOGY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; ACUTE KIDNEY INJURY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CONVALESCENCE; DRUG EFFECTS; FIBROSIS; KIDNEY TUBULE; METABOLISM; PATHOLOGY;

ACUTE KIDNEY INJURY; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; ISOPROSTANES; KIDNEY TUBULES; MALE; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS; PYRIDOXAMINE; RECOVERY OF FUNCTION; VITAMIN B COMPLEX;

EID: 84984629340     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00056.2016     Document Type: Article

References (70)

1. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63: 2123–2133, 2003.
2. Arora MK, Singh UK. Oxidative stress: meeting multiple targets in pathogenesis of diabetic nephropathy. Curr Drug Targets 15: 531–538, 2014.
3. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 380: 756–766, 2012.
4. Billings FT, Ball SK, Roberts LJ, Pretorius M. Postoperative acute kidney injury is associated with hemoglobinemia and an enhanced oxidative stress response. Free Rad Biol Med 50: 1480–1487, 2011.
5. Billings FT, Petracek MR, Roberts LJ 2nd, Pretorius M. Perioperative intravenous acetaminophen attenuates lipid peroxidation in adults undergoing cardiopulmonary bypass: a randomized clinical trial. PloS one 10: e0117625, 2015.
6. Billings FT, Shaw AD. Clinical trial endpoints in acute kidney injury. Nephron Clin Pract 127: 89–93, 2014.
7. Boutaud O, Moore KP, Reeder BJ, Harry D, Howie AJ, Wang S, Carney CK, Masterson TS, Amin T, Wright DW, Wilson MT, Oates JA, Roberts LJ 2nd. Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proc Natl Acad Sci USA 107: 2699–2704, 2010.
8. Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE 2nd, Perkins RM. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 81: 477–485, 2012.
9. Byun K, Bayarsaikhan E, Kim D, Kim CY, Mook-Jung I, Paek SH, Kim SU, Yamamoto T, Won MH, Song BJ, Park YM, Lee B. Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer’s disease. PloS One 7: e37917, 2012.
10. Charvet CD, Saadane A, Wang M, Salomon RG, Brunengraber H, Turko IV, Pikuleva IA. Pretreatment with pyridoxamine mitigates isole-vuglandin-associated retinal effects in mice exposed to bright light. J Biol Chem 288: 29267–29280, 2013.
11. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 79: 1361–1369, 2012.
12. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 82: 516–524, 2012.
13. Chetyrkin SV, Kim D, Belmont JM, Scheinman JI, Hudson BG, Voziyan PA. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Kidney Int 67: 53–60, 2005.
14. Chiba T, Skrypnyk NI, Skvarca LB, Penchev R, Zhang KX, Rochon ER, Fall JL, Paueksakon P, Yang H, Alford CE, Roman BL, Zhang MZ, Harris R, Hukriede NA, de Caestecker MP. Retinoic acid signaling coordinates macrophage-dependent injury and repair after AKI. J Am Soc Nephrol 27: 495–508, 2016.
15. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81: 442–448, 2012.
16. Cosentino CC, Skrypnyk NI, Brilli LL, Chiba T, Novitskaya T, Woods C, West J, Korotchenko VN, McDermott L, Day BW, Davidson AJ, Harris RC, de Caestecker MP, Hukriede NA. Histone deacetylase inhibitor enhances recovery after AKI. J Am Soc Nephrol 24: 943–953, 2013.
17. Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 76: 8–11, 1987.
18. Davies SS. Modulation of protein function by isoketals and levuglandins. Subcell Biochem 49: 49–70, 2008.
19. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939–950, 2002.
20. Dwyer JP, Greco BA, Umanath K, Packham D, Fox JW, Peterson R, Broome BR, Greene LE, Sika M, Lewis JB. Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. Nephron 129: 22–28, 2015.
21. Fessel JP, Porter NA, Moore KP, Sheller JR, Roberts LJ 2nd. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci USA 99: 16713–16718, 2002.
22. Forman HJ, Augusto O, Brigelius-Flohe R, Dennery PA, Kalyanaraman B, Ischiropoulos H, Mann GE, Radi R, Roberts LJ 2nd, Vina J, Davies KJ. Even free radicals should follow some rules: a guide to free radical research terminology and methodology. Free Rad Biol Med 78: 233–235, 2015.
23. Grove KJ, Voziyan PA, Spraggins JM, Wang S, Paueksakon P, Harris RC, Hudson BG, Caprioli RM. Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles. J Lipid Res 55: 1375–1385, 2014.
24. Hagiwara S, Gohda T, Tanimoto M, Ito T, Murakoshi M, Ohara I, Yamazaki T, Matsumoto M, Horikoshi S, Funabiki K, Tomino Y. Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice. Metab Clin Exp 58: 934–945, 2009.
25. Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol 45: 188–195, 2010.
26. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is upregulated in renal cells after injury. J Biol Chem 273: 4135–4142, 1998.
27. Janz DR, Bastarache JA, Rice TW, Bernard GR, Warren MA, Wickersham N, Sills G, Oates JA, Roberts LJ 2nd, Ware LB, Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis Study Group. Randomized, placebo-controlled trial of acetaminophen for the reduction of oxidative injury in severe sepsis: the Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis trial. Crit Care Med 43: 534–541, 2015.
28. Koyner JL, Sher Ali R, Murray Antioxidants PT. Do they have a place in the prevention or therapy of acute kidney injury? Nephron Exp Nephrol 109: e109–e117, 2008.
29. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R. Acute kidney injury: an increasing global concern. Lancet 382: 170–179, 2013.
30. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 23: 131–136, 2012.
31. Liu P, Feng Y, Wang Y, Zhou Y, Zhao L. Protective effect of vitamin E against acute kidney injury. Biomed Mat Eng 26, Suppl 1: S2133–S2144, 2015.
32. Lu A, Miao M, Schoeb TR, Agarwal A, Murphy-Ullrich JE. Blockade of TSP1-dependent TGF-beta activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol 178: 2573–2586, 2011.
33. Madu H, Avance J, Chetyrkin S, Darris C, Rose KL, Sanchez OA, Hudson B, Voziyan P. Pyridoxamine protects proteins from damage by hypohalous acids in vitro and in vivo. Free Rad Biol Med 89: 83–90, 2015.
34. Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Preven 4: 20–27, 2015.
35. Martines AM, Masereeuw R, Tjalsma H, Hoenderop JG, Wetzels JF, Swinkels DW. Iron metabolism in the pathogenesis of iron-induced kidney injury. Nat Rev Nephrol 9: 385–398, 2013.
36. Merrill AH Jr, Henderson JM. Vitamin B6 metabolism by human liver. Ann NY Acad Sci 585: 110–117, 1990.
37. Milne GL, Dai Q, Roberts LJ 2nd. The isoprostanes–25 years later. Biochim Biophys Acta 1851: 433–445, 2015.
38. Milne GL, Gao BL, Terry ES, Zackert WE, Sanchez SC. Measurement of F2-isoprostanes and isofurans using gas chromatography-mass spectrometry. Free Rad Biol Med 59: 36–44, 2013.
39. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534–2543, 2003.
40. Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Ohara I, Toyoda H, Ishikawa Y, Horikoshi S, Tomino Y. Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Diabetes Res Clin Pract 83: 183–189, 2009.
41. Novitskaya T, McDermott L, Zhang KX, Chiba T, Paueksakon P, Hukriede NA, de Caestecker MP. A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury. Am J Physiol Renal Physiol 306: F496–F504, 2014.
42. Nowotny K, Jung T, Hohn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 5: 194–222, 2015.
43. Okamura DM, Pennathur S. The balance of powers: redox regulation of fibrogenic pathways in kidney injury. Redox Biol 6: 495–504, 2015.
44. Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. BioMed Res Int 2014: 967826, 2014.
45. Panizo N, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, Moreno JA. Molecular mechanisms and novel therapeutic approaches to rhabdomyolysis-induced acute kidney injury. Kidney Blood Press Res 40: 520–532, 2015.
46. Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. Nat Rev Nephrol 10: 193–207, 2014.
47. Roberts LJ 2nd, Oates JA, Linton MF, Fazio S, Meador BP, Gross MD, Shyr Y, Morrow JD. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Rad Biol Med 43: 1388–1393, 2007.
48. Rodrigues T, Matafome P, Santos-Silva D, Sena C, Seica R. Reduction of methylglyoxal-induced glycation by pyridoxamine improves adipose tissue microvascular lesions. J Diabetes Res 2013: 690650, 2013.
49. Semchyshyn HM. Reactive carbonyl species in vivo: generation and dual biological effects. Sci World J 2014: 417842, 2014.
50. Shum HP, Yan WW, Chan TM. Recent knowledge on the pathophysiology of septic acute kidney injury: a narrative review. J Crit Care 31: 82–89, 2016.
51. Simpson SA, Zaccagni H, Bichell DP, Christian KG, Mettler BA, Donahue BS, Roberts LJ, Pretorius M. Acetaminophen attenuates lipid peroxidation in children undergoing cardiopulmonary bypass. Pediatr Crit Care Med 15: 503–510, 2014.
52. Skrypnyk NI, Harris RC, de Caestecker MP. Ischemia-reperfusion model of acute kidney injury and post injury fibrosis in mice. J Vis Exp 9: 2013.
53. Skrypnyk NI, Sanker S, Brilli-Skvarca L, Novitskaya T, Woods C, Chiba T, Patel K, Goldberg ND, McDermott L, Vinson PN, Calcutt MW, Huryn DM, Vernetti LA, Vogt A, Hukriede N, de Caestecker MP. Delayed treatment with PTBA analogs reduces post injury renal fibrosis after kidney injury. Am J Physiol Renal Physiol ajprenal In press.
54. Spandidos A, Wang XW, Wang HJ, Dragnev S, Thurber T, Seed B. A comprehensive collection of experimentally validated primers for Polymerase Chain Reaction quantitation of murine transcript abundance. BMC Genomics 9: 2008.
55. Takahashi N, Boysen G, Li F, Li Y, Swenberg JA. Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 71: 266–271, 2007.
56. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, Yamada K, Ito T, Matsumoto M, Horikoshi S, Tomino Y. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metab Clin Exp 56: 160–167, 2007.
57. Thotala D, Chetyrkin S, Hudson B, Hallahan D, Voziyan P, Yazlovitskaya E. Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis. Free Rad Biol Med 47: 779–785, 2009.
58. Valko M, Jomova K, Rhodes CJ, Kuca K, Musilek K. Redox- and non-redox-metal-induced formation of free radicals and their role in human disease. Arch Toxicol 90: 1–37, 2016.
59. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 62: 1671–1681, 2005.
60. Voziyan PA, Khalifah RG, Thibaudeau C, Yildiz A, Jacob J, Serianni AS, Hudson BG. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem 278: 46616–46624, 2003.
61. Voziyan PA, Metz TO, Baynes JW, Hudson BG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277: 3397–3403, 2002.
62. Wald R, Quinn RR, Adhikari NK, Burns KE, Friedrich JO, Garg AX, Harel Z, Hladunewich MA, Luo J, Mamdani M, Perl J, Ray JG, University of Toronto Acute Kidney Injury Research Group. Risk of chronic dialysis and death following acute kidney injury. Am J Med 125: 585–593, 2012.
63. Wang CH, Wu ET, Wu MS, Tsai MS, Ko YH, Chang RW, Chang CY, Chang KC. Pyridoxamine protects against mechanical defects in cardiac ageing in rats: studies on load dependence of myocardial relaxation. Exp Physiol 99: 1488–1498, 2014.
64. Wang X, Bonventre JV, Parrish AR. The aging kidney: increased susceptibility to nephrotoxicity. Int J Mol Sci 15: 15358–15376, 2014.
65. Weisbord SD, Gallagher M, Kaufman J, Cass A, Parikh CR, Chertow GM, Shunk KA, McCullough PA, Fine MJ, Mor MK, Lew RA, Huang GD, Conner TA, Brophy MT, Lee J, Soliva S, Palevsky PM. Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin J Am Soc Nephrol 8: 1618–1631, 2013.
66. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 27: 605–614, 2007.
67. Wu VC, Huang TM, Lai CF, Shiao CC, Lin YF, Chu TS, Wu PC, Chao CT, Wang JY, Kao TW, Young GH, Tsai PR, Tsai HB, Wang CL, Wu MS, Chiang WC, Tsai IJ, Hu FC, Lin SL, Chen YM, Tsai TJ, Ko WJ, Wu KD. Acute-on-chronic kidney injury at hospital discharge is associated with long-term dialysis and mortality. Kidney Int 80: 1222–1230, 2011.
68. Yazlovitskaya EM, Voziyan PA, Manavalan T, Yarbrough WG, Ivanova AV. Cellular oxidative stress response mediates radiosensitivity in Fus1-deficient mice. Cell Death Dis 6: e1652, 2015.
69. Zacharias M, Mugawar M, Herbison GP, Walker RJ, Hovhannisyan K, Sivalingam P, Conlon NP. Interventions for protecting renal function in the perioperative period. Cochrane Database Sys Rev 9: CD003590, 2013.
70. Zheng F, Zeng YJ, Plati AR, Elliot SJ, Berho M, Potier M, Striker LJ, Striker GE. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 70: 507–514, 2006.